Topic: GPCR biased ligands
A Scripps Research team identified the GPR139 receptor as a regulator that could reduce opioids' toxic withdrawal effects.
BI will work with Vanderbilt to develop novel small molecules that they believe will relieve symptoms including memory loss.
Escient Pharmaceuticals launched with $40 million to develop GPCR-targeted drugs for a wide range of unserved indications.
Astellas has struck a deal to buy Ogeda for €500 million upfront to gain a potential nonhormonal treatment for menopausal hot flashes.